O valor prognóstico da quantificação da carga leucêmica ao diagnóstico utilizando o gene GUS como gene controle em pacientes com Leucemia Mieloide Crônica
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Biblioteca Digital de Teses e Dissertações da UERJ |
Texto Completo: | http://www.bdtd.uerj.br/handle/1/17747 |
Resumo: | Chronic myeloid leukemia (CML) is a hematologic malignancy characterized by the presence of a reciprocal translocation between chromosomes 9 and 22, resulting in a marker chromosome called "Philadelphia" (Ph). The fusion gene formed (BCR –ABL) leads to the production of a messenger RNA and expression of chimeric fusion protein (BCR -ABL) with constitutive tyrosine kinase activity, deregulating several signaling pathways and causing, for example, increased cell proliferation, resistance to apoptosis, and modification of the characteristics of cell adhesion. The development of the first target-specific inhibitory drug of tyrosine kinase (ITK) activity and its introduction into clinical practice radically changed the treatment of CML and made it necessary to establish new parameters for defining therapeutic response. Such a response is established according to increasing levels of sensitivity: Hematologic response (HR), Cytogenetic Response (CgR) or Molecular Response (MR). Aiming a standardization of clinical management, the European Consortium LeukemiaNet (ELN) grouped patients with CML in different operational response categories. The required time to a patient reach MR is considered an early predictor of therapeutic response throughout his clinical course. Recent studies establishing an association between early MR obtaining and durability of complete CgR. In 2013, such response categories were updated taking into account the existence of 2nd generation ITK and molecular assessment already at three months after initiation of ITK. Thus, the concept of the value of MR at three months is now the hallmark of early response, with greater prognostic value independent of other parameters. Therefore, the application of an appropriate internal control methodology is essential for an accurate determination of RM. To correct the variations in RNA quality and quantity and to calculate the sensitivity of the measurement by real-time PCR (qRT -PCR), a control gene (CG) of the transcript should be amplified in parallel to the fusion gene. Studies have shown that the CG BCR and ABL, the most widely used, do not have linearity when transcript levels are elevated (> 10%), because they have interference with the BCR-ABL gene fusion with false values. Thus, the question if the leukemic burden at diagnosis and the rate of decay of this burden can be used as predictive early biomarkers and therapeutic response, this question can not be answered with the use of ABL and BCR GC. In this study, 204 patients were analyzed for correlation between CgR and transcripts levels BCR-ABL/ABLEI average of 0.6% (n = 97) where BCR-ABL/ABLEI < 1 % (p < 0, 0001). It was possible to evaluate 31 patients for the study GUS gene as the molecular GC reviews . By measuring the levels of BCR-ABL at diagnosis, patients classified as responders had levels BCR-ABL/ABL% of 87.84 (26.8 to 164.5) and levels of BCR-ABL/GUS% of 28.38 (8.2 to 217) (p < 0.0001). Patients classified as non-responders had levels BCR-ABL/ABL% of 93.72 (30.87 to 184.5) and levels of BCR-ABL/GUS% of 40.92 (17.21 to 96.85) (p = 0.89) |
id |
UERJ_ed704d19d36112a2148ad3ef9e8471e8 |
---|---|
oai_identifier_str |
oai:www.bdtd.uerj.br:1/17747 |
network_acronym_str |
UERJ |
network_name_str |
Biblioteca Digital de Teses e Dissertações da UERJ |
repository_id_str |
2903 |
spelling |
Renault, Ilana ZalcbergSolza, CristianaMaioli, Maria Christina PaixãoSoares, Andréa RibeiroCappelletti, Paola AlejandraCruz, Marina Magnagocbabdtd@gmail.com2022-05-17T13:38:22Z2014-07-18CRUZ, Marina Magnago. O valor prognóstico da quantificação da carga leucêmica ao diagnóstico utilizando o gene GUS como gene controle em pacientes com Leucemia Mieloide Crônica. 2014. 80 f. Dissertação (Mestrado em Ciências Médicas) - Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, 2014.http://www.bdtd.uerj.br/handle/1/17747Chronic myeloid leukemia (CML) is a hematologic malignancy characterized by the presence of a reciprocal translocation between chromosomes 9 and 22, resulting in a marker chromosome called "Philadelphia" (Ph). The fusion gene formed (BCR –ABL) leads to the production of a messenger RNA and expression of chimeric fusion protein (BCR -ABL) with constitutive tyrosine kinase activity, deregulating several signaling pathways and causing, for example, increased cell proliferation, resistance to apoptosis, and modification of the characteristics of cell adhesion. The development of the first target-specific inhibitory drug of tyrosine kinase (ITK) activity and its introduction into clinical practice radically changed the treatment of CML and made it necessary to establish new parameters for defining therapeutic response. Such a response is established according to increasing levels of sensitivity: Hematologic response (HR), Cytogenetic Response (CgR) or Molecular Response (MR). Aiming a standardization of clinical management, the European Consortium LeukemiaNet (ELN) grouped patients with CML in different operational response categories. The required time to a patient reach MR is considered an early predictor of therapeutic response throughout his clinical course. Recent studies establishing an association between early MR obtaining and durability of complete CgR. In 2013, such response categories were updated taking into account the existence of 2nd generation ITK and molecular assessment already at three months after initiation of ITK. Thus, the concept of the value of MR at three months is now the hallmark of early response, with greater prognostic value independent of other parameters. Therefore, the application of an appropriate internal control methodology is essential for an accurate determination of RM. To correct the variations in RNA quality and quantity and to calculate the sensitivity of the measurement by real-time PCR (qRT -PCR), a control gene (CG) of the transcript should be amplified in parallel to the fusion gene. Studies have shown that the CG BCR and ABL, the most widely used, do not have linearity when transcript levels are elevated (> 10%), because they have interference with the BCR-ABL gene fusion with false values. Thus, the question if the leukemic burden at diagnosis and the rate of decay of this burden can be used as predictive early biomarkers and therapeutic response, this question can not be answered with the use of ABL and BCR GC. In this study, 204 patients were analyzed for correlation between CgR and transcripts levels BCR-ABL/ABLEI average of 0.6% (n = 97) where BCR-ABL/ABLEI < 1 % (p < 0, 0001). It was possible to evaluate 31 patients for the study GUS gene as the molecular GC reviews . By measuring the levels of BCR-ABL at diagnosis, patients classified as responders had levels BCR-ABL/ABL% of 87.84 (26.8 to 164.5) and levels of BCR-ABL/GUS% of 28.38 (8.2 to 217) (p < 0.0001). Patients classified as non-responders had levels BCR-ABL/ABL% of 93.72 (30.87 to 184.5) and levels of BCR-ABL/GUS% of 40.92 (17.21 to 96.85) (p = 0.89)A Leucemia Mieloide Crônica (LMC) é uma neoplasia hematológica caracterizada pela presença de uma translocação recíproca entre os cromossomos 9 e 22, que resulta em um cromossomo marcador chamado “Philadelphia” (Ph). O gene de fusão formado (BCR-ABL) leva à produção de um RNA mensageiro quimérico e a expressão da proteína de fusão (BCR-ABL) com atividade de tirosina quinase constitutiva, desregulando diversas vias de sinalização e provocando, por exemplo, aumento da proliferação celular, resistência à apoptose e modificação das características de adesão celular. O desenvolvimento da primeira droga alvo-específica inibidora da atividade tirosina quinase (ITK) e a sua introdução na prática clínica modificou radicalmente o tratamento da LMC e tornou necessário o estabelecimento de novos parâmetros para definição de resposta terapêutica. Tal resposta é estabelecida de acordo com níveis crescentes de sensibilidade: Resposta Hematológica (RH), Resposta Citogenética (RCg) ou Resposta Molecular (RM). Visando a uniformização da conduta clínica, o Consórcio Europeu LeukemiaNet (ELN) agrupou os pacientes com LMC em distintas categorias operacionais de resposta. O tempo necessário para um paciente atingir a RM é tido como fator preditivo precoce da resposta terapêutica ao longo de sua evolução clínica. Estudos recentes estabelecem uma associação entre obtenção precoce de RM maior e durabilidade da RCg completa. Em 2013, tais categorias de resposta foram atualizadas levando em consideração a existência dos ITK de 2a geração e a avaliação molecular já aos três meses após o início do ITK. Desta maneira, o conceito do valor da RM aos três meses é hoje o marco de resposta precoce com maior valor prognóstico independente de outros parâmetros analisados. Diante disso, a aplicação de um controle interno adequado à metodologia é essencial para uma determinação precisa da RM. Para corrigir as variações na qualidade e quantidade de RNA e calcular a sensibilidade da medição por PCR em tempo real (qRT-PCR), um gene de controle (GC) da transcrição deve ser amplificado em paralelo ao gene de fusão. Estudos demonstram que os GC, BCR e ABL, mais amplamente utilizados, não possuem linearidade quando os níveis de transcritos são elevados (> 10%), porque possuem interferentes com o gene de fusão BCR-ABL gerando valores falsos. Desta forma, se a carga leucêmica ao diagnóstico e a velocidade de decaimento desta podem ser utilizadas como biomarcadores preditivos e precoces da resposta terapêutica não pode ser respondida com o uso do GC ABL e BCR. Neste estudo, foram avaliados 204 pacientes para correlação entre RCg e níveis de transcrito BCR-ABL, e observamos que em pacientes com RCg completa a média de transcritos BCR-ABL/ABLEI foi de 0,6 % (n = 97) ou seja BCR-ABL/ABLEI < 1% (p<0,0001). Foi possível avaliar 31 pacientes para o estudo do gene GUS como GC das avaliações moleculares. Ao medirmos os níveis de transcritos BCR-ABL ao diagnóstico, os pacientes classificados como respondedores tiveram níveis de BCR-ABL/ABL% de 87,84 (26,8 – 164,5) e níveis de BCR-ABL/GUS% de 28,38 (8,2 – 217) (p<0,0001). Os pacientes classificados como não respondedores tiveram níveis de BCR-ABL/ABL% de 93,72 (30,87 – 184,5) e níveis de BCR-ABL/GUS% de 40,92 (17,21 – 96,85) (p=0,89).Submitted by Thais Vieira NPROTEC (thaisvieira.uerj@gmail.com) on 2022-05-17T13:38:22Z No. of bitstreams: 1 Dissertação - Marina Magnano Cruz - 2014 - Completa.pdf: 2643570 bytes, checksum: 64d0e369e6c03758ecb3899afd240fcd (MD5)Made available in DSpace on 2022-05-17T13:38:22Z (GMT). No. of bitstreams: 1 Dissertação - Marina Magnano Cruz - 2014 - Completa.pdf: 2643570 bytes, checksum: 64d0e369e6c03758ecb3899afd240fcd (MD5) Previous issue date: 2014-07-18application/pdfporUniversidade do Estado do Rio de JaneiroPrograma de Pós-Graduação em Ciências MédicasUERJBrasilCentro Biomédico::Faculdade de Ciências MédicasLeucemia mielóide de fase crônicaPrognósticoAnálise citogenéticaApoptoseChronic myeloid leukemiaReal time PCRImatinib mesylateGUS geneCIENCIAS DA SAUDE::MEDICINA::CLINICA MEDICA::CANCEROLOGIAO valor prognóstico da quantificação da carga leucêmica ao diagnóstico utilizando o gene GUS como gene controle em pacientes com Leucemia Mieloide CrônicaThe prognostic value of quantification of leukemic burden at diagnosis using the GUS gene as control gene in patients with Chronic Myeloid Lekemiainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/openAccessreponame:Biblioteca Digital de Teses e Dissertações da UERJinstname:Universidade do Estado do Rio de Janeiro (UERJ)instacron:UERJORIGINALDissertação - Marina Magnano Cruz - 2014 - Completa.pdfDissertação - Marina Magnano Cruz - 2014 - Completa.pdfapplication/pdf2643570http://www.bdtd.uerj.br/bitstream/1/17747/2/Disserta%C3%A7%C3%A3o+-+Marina+Magnano+Cruz++-+2014+-+Completa.pdf64d0e369e6c03758ecb3899afd240fcdMD52LICENSElicense.txtlicense.txttext/plain; charset=utf-82123http://www.bdtd.uerj.br/bitstream/1/17747/1/license.txte5502652da718045d7fcd832b79fca29MD511/177472022-05-18 09:18:13.805oai:www.bdtd.uerj.br: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Biblioteca Digital de Teses e Dissertaçõeshttp://www.bdtd.uerj.br/PUBhttps://www.bdtd.uerj.br:8443/oai/requestbdtd.suporte@uerj.bropendoar:29032022-05-18T12:18:13Biblioteca Digital de Teses e Dissertações da UERJ - Universidade do Estado do Rio de Janeiro (UERJ)false |
dc.title.por.fl_str_mv |
O valor prognóstico da quantificação da carga leucêmica ao diagnóstico utilizando o gene GUS como gene controle em pacientes com Leucemia Mieloide Crônica |
dc.title.alternative.eng.fl_str_mv |
The prognostic value of quantification of leukemic burden at diagnosis using the GUS gene as control gene in patients with Chronic Myeloid Lekemia |
title |
O valor prognóstico da quantificação da carga leucêmica ao diagnóstico utilizando o gene GUS como gene controle em pacientes com Leucemia Mieloide Crônica |
spellingShingle |
O valor prognóstico da quantificação da carga leucêmica ao diagnóstico utilizando o gene GUS como gene controle em pacientes com Leucemia Mieloide Crônica Cruz, Marina Magnago Leucemia mielóide de fase crônica Prognóstico Análise citogenética Apoptose Chronic myeloid leukemia Real time PCR Imatinib mesylate GUS gene CIENCIAS DA SAUDE::MEDICINA::CLINICA MEDICA::CANCEROLOGIA |
title_short |
O valor prognóstico da quantificação da carga leucêmica ao diagnóstico utilizando o gene GUS como gene controle em pacientes com Leucemia Mieloide Crônica |
title_full |
O valor prognóstico da quantificação da carga leucêmica ao diagnóstico utilizando o gene GUS como gene controle em pacientes com Leucemia Mieloide Crônica |
title_fullStr |
O valor prognóstico da quantificação da carga leucêmica ao diagnóstico utilizando o gene GUS como gene controle em pacientes com Leucemia Mieloide Crônica |
title_full_unstemmed |
O valor prognóstico da quantificação da carga leucêmica ao diagnóstico utilizando o gene GUS como gene controle em pacientes com Leucemia Mieloide Crônica |
title_sort |
O valor prognóstico da quantificação da carga leucêmica ao diagnóstico utilizando o gene GUS como gene controle em pacientes com Leucemia Mieloide Crônica |
author |
Cruz, Marina Magnago |
author_facet |
Cruz, Marina Magnago cbabdtd@gmail.com |
author_role |
author |
author2 |
cbabdtd@gmail.com |
author2_role |
author |
dc.contributor.advisor1.fl_str_mv |
Renault, Ilana Zalcberg |
dc.contributor.advisor-co1.fl_str_mv |
Solza, Cristiana |
dc.contributor.referee1.fl_str_mv |
Maioli, Maria Christina Paixão |
dc.contributor.referee2.fl_str_mv |
Soares, Andréa Ribeiro |
dc.contributor.referee3.fl_str_mv |
Cappelletti, Paola Alejandra |
dc.contributor.author.fl_str_mv |
Cruz, Marina Magnago cbabdtd@gmail.com |
contributor_str_mv |
Renault, Ilana Zalcberg Solza, Cristiana Maioli, Maria Christina Paixão Soares, Andréa Ribeiro Cappelletti, Paola Alejandra |
dc.subject.por.fl_str_mv |
Leucemia mielóide de fase crônica Prognóstico Análise citogenética Apoptose |
topic |
Leucemia mielóide de fase crônica Prognóstico Análise citogenética Apoptose Chronic myeloid leukemia Real time PCR Imatinib mesylate GUS gene CIENCIAS DA SAUDE::MEDICINA::CLINICA MEDICA::CANCEROLOGIA |
dc.subject.eng.fl_str_mv |
Chronic myeloid leukemia Real time PCR Imatinib mesylate GUS gene |
dc.subject.cnpq.fl_str_mv |
CIENCIAS DA SAUDE::MEDICINA::CLINICA MEDICA::CANCEROLOGIA |
description |
Chronic myeloid leukemia (CML) is a hematologic malignancy characterized by the presence of a reciprocal translocation between chromosomes 9 and 22, resulting in a marker chromosome called "Philadelphia" (Ph). The fusion gene formed (BCR –ABL) leads to the production of a messenger RNA and expression of chimeric fusion protein (BCR -ABL) with constitutive tyrosine kinase activity, deregulating several signaling pathways and causing, for example, increased cell proliferation, resistance to apoptosis, and modification of the characteristics of cell adhesion. The development of the first target-specific inhibitory drug of tyrosine kinase (ITK) activity and its introduction into clinical practice radically changed the treatment of CML and made it necessary to establish new parameters for defining therapeutic response. Such a response is established according to increasing levels of sensitivity: Hematologic response (HR), Cytogenetic Response (CgR) or Molecular Response (MR). Aiming a standardization of clinical management, the European Consortium LeukemiaNet (ELN) grouped patients with CML in different operational response categories. The required time to a patient reach MR is considered an early predictor of therapeutic response throughout his clinical course. Recent studies establishing an association between early MR obtaining and durability of complete CgR. In 2013, such response categories were updated taking into account the existence of 2nd generation ITK and molecular assessment already at three months after initiation of ITK. Thus, the concept of the value of MR at three months is now the hallmark of early response, with greater prognostic value independent of other parameters. Therefore, the application of an appropriate internal control methodology is essential for an accurate determination of RM. To correct the variations in RNA quality and quantity and to calculate the sensitivity of the measurement by real-time PCR (qRT -PCR), a control gene (CG) of the transcript should be amplified in parallel to the fusion gene. Studies have shown that the CG BCR and ABL, the most widely used, do not have linearity when transcript levels are elevated (> 10%), because they have interference with the BCR-ABL gene fusion with false values. Thus, the question if the leukemic burden at diagnosis and the rate of decay of this burden can be used as predictive early biomarkers and therapeutic response, this question can not be answered with the use of ABL and BCR GC. In this study, 204 patients were analyzed for correlation between CgR and transcripts levels BCR-ABL/ABLEI average of 0.6% (n = 97) where BCR-ABL/ABLEI < 1 % (p < 0, 0001). It was possible to evaluate 31 patients for the study GUS gene as the molecular GC reviews . By measuring the levels of BCR-ABL at diagnosis, patients classified as responders had levels BCR-ABL/ABL% of 87.84 (26.8 to 164.5) and levels of BCR-ABL/GUS% of 28.38 (8.2 to 217) (p < 0.0001). Patients classified as non-responders had levels BCR-ABL/ABL% of 93.72 (30.87 to 184.5) and levels of BCR-ABL/GUS% of 40.92 (17.21 to 96.85) (p = 0.89) |
publishDate |
2014 |
dc.date.issued.fl_str_mv |
2014-07-18 |
dc.date.accessioned.fl_str_mv |
2022-05-17T13:38:22Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
CRUZ, Marina Magnago. O valor prognóstico da quantificação da carga leucêmica ao diagnóstico utilizando o gene GUS como gene controle em pacientes com Leucemia Mieloide Crônica. 2014. 80 f. Dissertação (Mestrado em Ciências Médicas) - Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, 2014. |
dc.identifier.uri.fl_str_mv |
http://www.bdtd.uerj.br/handle/1/17747 |
identifier_str_mv |
CRUZ, Marina Magnago. O valor prognóstico da quantificação da carga leucêmica ao diagnóstico utilizando o gene GUS como gene controle em pacientes com Leucemia Mieloide Crônica. 2014. 80 f. Dissertação (Mestrado em Ciências Médicas) - Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, 2014. |
url |
http://www.bdtd.uerj.br/handle/1/17747 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade do Estado do Rio de Janeiro |
dc.publisher.program.fl_str_mv |
Programa de Pós-Graduação em Ciências Médicas |
dc.publisher.initials.fl_str_mv |
UERJ |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
Centro Biomédico::Faculdade de Ciências Médicas |
publisher.none.fl_str_mv |
Universidade do Estado do Rio de Janeiro |
dc.source.none.fl_str_mv |
reponame:Biblioteca Digital de Teses e Dissertações da UERJ instname:Universidade do Estado do Rio de Janeiro (UERJ) instacron:UERJ |
instname_str |
Universidade do Estado do Rio de Janeiro (UERJ) |
instacron_str |
UERJ |
institution |
UERJ |
reponame_str |
Biblioteca Digital de Teses e Dissertações da UERJ |
collection |
Biblioteca Digital de Teses e Dissertações da UERJ |
bitstream.url.fl_str_mv |
http://www.bdtd.uerj.br/bitstream/1/17747/2/Disserta%C3%A7%C3%A3o+-+Marina+Magnano+Cruz++-+2014+-+Completa.pdf http://www.bdtd.uerj.br/bitstream/1/17747/1/license.txt |
bitstream.checksum.fl_str_mv |
64d0e369e6c03758ecb3899afd240fcd e5502652da718045d7fcd832b79fca29 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Biblioteca Digital de Teses e Dissertações da UERJ - Universidade do Estado do Rio de Janeiro (UERJ) |
repository.mail.fl_str_mv |
bdtd.suporte@uerj.br |
_version_ |
1792352359384350720 |